LH2-051

Overview

LH2-051, a lysosome-enhancing compound (LYEC), is a brain-penetrant dopamine transporter ( DAT ) inhibitor ( K i : 0.95 μM). LH2-051 inhibits DAT -mediated dopamine uptake with an IC 50 of 3.0 μM. LH2-051 promotes nuclear translocation of TFEB and lysosome biogenesis. LH2-051 improves the memory of amyloid precursor protein (APP)/Presenilin 1 (PS1) mice. LH2-051 can be used for the study of Alzheimer’s disease.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Dopamine Transporter | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-161723
• CAS No.: 2358754-22-8
• Molecular Formula: C27H34N2O3
• Molecular Weight: 434.57
• Purity: 99.85%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (5.75 mM); Clear solution
• Availability: In-stock

Source

Original product source